MANKIND PHARMA announced FDA approval for ANDA214230 on July 28, 2026, a decision expected to strategically expand its product portfolio and drive revenue growth through increased market share. The company is positioned to capitalize on the significant market potential of this approval, bringing essential healthcare solutions to a wider demographic.